{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:00:43Z","timestamp":1788667243290,"version":"build-2803163510"},"reference-count":176,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest cancers, with a 5-year survival rate of 13% and broad resistance to therapy. It is driven by severe tumor hypoxia from desmoplasia, aberrant vasculature, and high interstitial pressure. Hypoxia stabilizes hypoxia-inducible factors (HIFs), reshaping the tumor microenvironment (TME) into a nutrient-poor, acidic milieu that fosters immune exclusion and suppression. While immune checkpoint inhibitors (ICIs) have revolutionized treatment, PDAC responses have been negligible. As hypoxia centrally drives PDAC\u2019s ICI-refractory TME, targeted alleviation could offer synergy with ICIs; however, no such combination is being applied in the clinic. One impediment could be the one-size-fits-all approach when investigating hypoxia-modifying therapy. Indeed, using hypoxia gene signatures, we and others have shown that PDAC tumors are not equally hypoxic, with patients having more hypoxic tumors experiencing worse survival and immunosuppressed TME. This review dissects hypoxia\u2019s mechanistic role in PDAC immune evasion and gives an update on the therapeutic advances that directly or indirectly target hypoxia, such as the inhibition of HIFs, hypoxia-activated prodrugs, and vascular and oxygen delivery approaches, with emphasis on their potential to enhance responses to ICIs. It further evaluates the need for hypoxia biomarkers and proposes gene signatures as detection tools to enable precision hypoxia modulation, potentially converting immune-cold PDAC into an ICI-responsive disease.<\/jats:p>","DOI":"10.3390\/ijms27093873","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:33:37Z","timestamp":1777376017000},"page":"3873","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-6000","authenticated-orcid":false,"given":"Raefa","family":"Abou Khouzam","sequence":"first","affiliation":[{"name":"Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman 4184, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-3117","authenticated-orcid":false,"given":"Shaima","family":"Salman","sequence":"additional","affiliation":[{"name":"Armstrong Oxygen Biology Research Center and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-3627","authenticated-orcid":false,"given":"Jerome","family":"Thiery","sequence":"additional","affiliation":[{"name":"INSERM UMR 1356, Next-Generation Immuno-Oncology Research and Therapy in Pediatric and Adult Cancer, Gustave Roussy, Faculty of Medicine, University Paris-Saclay, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-5940","authenticated-orcid":false,"given":"Rania","family":"Zaarour","sequence":"additional","affiliation":[{"name":"Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman 4184, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visar","family":"Vela","sequence":"additional","affiliation":[{"name":"Gastrointestinal Research Unit, Department of General Surgery and Surgical Oncology, Cantonal Hospital Aarau, Tellstrasse 25, CH-5001 Aarau, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4158-4666","authenticated-orcid":false,"given":"Perparim","family":"Limani","sequence":"additional","affiliation":[{"name":"Swiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland"},{"name":"Department of Surgery & Transplantation, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-0943","authenticated-orcid":false,"given":"Bassam","family":"Janji","sequence":"additional","affiliation":[{"name":"Department of Cancer Research, Luxembourg Institute of Health, Tumor Immunotherapy and Microenvironment (TIME) Group, 6A, Rue Nicolas-Ernest Barbl\u00e9, L-1210 Luxembourg City, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Chouaib","sequence":"additional","affiliation":[{"name":"Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman 4184, United Arab Emirates"},{"name":"INSERM UMR 1356, Next-Generation Immuno-Oncology Research and Therapy in Pediatric and Adult Cancer, Gustave Roussy, Faculty of Medicine, University Paris-Saclay, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Abou Khouzam, R., Lehn, J.M., Mayr, H., Clavien, P.A., Wallace, M.B., Ducreux, M., Limani, P., and Chouaib, S. (2023). Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. Cancers, 15.","DOI":"10.3390\/cancers15041235"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1097\/MPA.0000000000002489","article-title":"Factors Driving Pancreatic Cancer Survival Rates","volume":"54","author":"Rahib","year":"2025","journal-title":"Pancreas"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0360-3016(00)00803-8","article-title":"Pancreatic tumors show high levels of hypoxia","volume":"48","author":"Koong","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1089\/ars.2007.1628","article-title":"Detection and characterization of tumor hypoxia using pO2 histography","volume":"9","author":"Vaupel","year":"2007","journal-title":"Antioxid. Redox Signal."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"G709","DOI":"10.1152\/ajpgi.90356.2008","article-title":"Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer","volume":"295","author":"Masamune","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/17474124.2016.1117386","article-title":"The role of hypoxia in pancreatic cancer: A potential therapeutic target?","volume":"10","author":"Erkan","year":"2016","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10456-018-9645-2","article-title":"Angiogenesis in pancreatic cancer: Current research status and clinical implications","volume":"22","author":"Li","year":"2019","journal-title":"Angiogenesis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/stcltm\/szad061","article-title":"Mechanisms of Breast Cancer Stem Cell Specification and Self-Renewal Mediated by Hypoxia-Inducible Factor 1","volume":"12","author":"Semenza","year":"2023","journal-title":"Stem Cells Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: Role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Abou Khouzam, R., Rao, S.P., Venkatesh, G.H., Zeinelabdin, N.A., Buart, S., Meylan, M., Nimmakayalu, M., Terry, S., and Chouaib, S. (2021). An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.680435"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00262-024-03632-6","article-title":"Clinical immunotherapy in pancreatic cancer","volume":"73","author":"Ye","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","article-title":"Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort","volume":"188","author":"Taieb","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","article-title":"Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT\/KEYNOTE-202 Trial","volume":"27","author":"Bockorny","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Maurer","year":"2022","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"216345","DOI":"10.1016\/j.canlet.2023.216345","article-title":"Hypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers","volume":"571","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10565-025-10092-w","article-title":"HypoxamiRs in pancreatic cancer: Master regulators of the hypoxic tumor microenvironment","volume":"41","author":"Maharati","year":"2025","journal-title":"Cell Biol. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Janji, B., and Chouaib, S. (2022). The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.880810"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Abou Khouzam, R., Zaarour, R.F., Brodaczewska, K., Azakir, B., Venkatesh, G.H., Thiery, J., Terry, S., and Chouaib, S. (2022). The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.828875"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bbcan.2018.07.002","article-title":"Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors","volume":"1870","author":"Samanta","year":"2018","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2326-6066.CIR-20-0111","article-title":"Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer","volume":"8","author":"Yang","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.4049\/jimmunol.1202702","article-title":"Tumor-derived lactate modifies antitumor immune response: Effect on myeloid-derived suppressor cells and NK cells","volume":"191","author":"Husain","year":"2013","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cmet.2015.06.023","article-title":"Hypoxia Induces Production of L-2-Hydroxyglutarate","volume":"22","author":"Intlekofer","year":"2015","journal-title":"Cell Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nchembio.2307","article-title":"L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH","volume":"13","author":"Intlekofer","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1158\/0008-5472.CAN-20-2562","article-title":"Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer","volume":"81","author":"Gupta","year":"2021","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Li, N., Li, Y., Li, Z., Huang, C., Yang, Y., Lang, M., Cao, J., Jiang, W., Xu, Y., and Dong, J. (2016). Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17060799"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Abdo, E., Ismail, M.A., Al Hadidi, S., Al-Mrahleh, M., Saleh, T., Zihlif, M., and Ababneh, N.A. (2025). Effect of cytotoxic CD8+ T-cells secretory proteins on hypoxic pancreatic cancer cells. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0311615"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"104016","DOI":"10.1016\/j.ebiom.2022.104016","article-title":"Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer","volume":"79","author":"Ye","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ou, Z., Lu, Y., Xu, D., and Luo, Z. (2023). Hypoxia mediates immune escape of pancreatic cancer cells by affecting miR-1275\/AXIN2 in natural killer cells. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1271603"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/0008-5472.CAN-17-3841","article-title":"Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN\/PI3Kgamma to Promote Pancreatic Cancer Metastasis","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/imm.13853","article-title":"Hypoxic tumour-derived exosomal miR-1290 exacerbates the suppression of CD8+ T cells by promoting M2 macrophage polarization","volume":"173","author":"Yang","year":"2024","journal-title":"Immunology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"111407","DOI":"10.1016\/j.intimp.2023.111407","article-title":"Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1","volume":"127","author":"Guo","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1080\/15476286.2019.1649585","article-title":"Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: Role of circ_0000977\/miR-153 axis","volume":"16","author":"Ou","year":"2019","journal-title":"RNA Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41435-024-00315-1","article-title":"Hypoxia-induced autophagy in pancreatic cancer counteracts the cytotoxicity of CD8+ T cells by inhibiting the expression of MHC-I","volume":"26","author":"Zhou","year":"2025","journal-title":"Genes. Immun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"C569","DOI":"10.1152\/ajpcell.00207.2015","article-title":"Hypoxia: A key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia","volume":"309","author":"Noman","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"102261","DOI":"10.1016\/j.tranon.2024.102261","article-title":"ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1alpha signaling","volume":"52","author":"Aziguli","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lan, X., Li, W., Zhao, K., Wang, J., Li, S., and Zhao, H. (2025). Revisiting the role of cancer-associated fibroblasts in tumor microenvironment. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1582532"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcmgh.2020.05.004","article-title":"Differential Contribution of Pancreatic Fibroblast Subsets to the Pancreatic Cancer Stroma","volume":"10","author":"Garcia","year":"2020","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wan, Y., Hu, Q., Sun, K., Shi, J., Liu, L., Zhang, X., Huang, J., Gong, C., Liu, J., and Wang, H. (2025). Heterogenous cancer-associated fibroblasts related tumor microenvironment marked by CD10\/KLF4\/TIAM1 were identified in pancreatic adenocarcinoma by integrated transcriptomics. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1557698"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1038\/s41467-018-07582-3","article-title":"Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing","volume":"9","author":"Bartoschek","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ziani, L., Chouaib, S., and Thiery, J. (2018). Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00414"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Geng, X., Chen, H., Zhao, L., Hu, J., Yang, W., Li, G., Cheng, C., Zhao, Z., Zhang, T., and Li, L. (2021). Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.655152"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival","volume":"25","author":"Ozdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2012.04.025","article-title":"Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness","volume":"324","author":"Comito","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_54","first-page":"31","article-title":"Role of carcinoma-associated fibroblasts and hypoxia in tumor progression","volume":"345","author":"Giaccia","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1950953","DOI":"10.1080\/2162402X.2021.1950953","article-title":"Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity","volume":"10","author":"Ziani","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00535-021-01800-4","article-title":"Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinoma","volume":"56","author":"Cannon","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.15252\/embr.201540107","article-title":"Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis","volume":"16","author":"Madsen","year":"2015","journal-title":"EMBO Rep."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kowalewski, K.M., Adair, S.J., Talkington, A., Wieder, J.J., Pitarresi, J.R., Perez-Vale, K., Chu, B., Dolatshahi, S., Sears, R., and Stanger, B.Z. (2025). Hypoxia-induced histone methylation and NF-kappaB activation in pancreas cancer fibroblasts promote EMT-supportive growth factor secretion. bioRxiv.","DOI":"10.1101\/2025.01.30.635486"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hirakawa, T., Yashiro, M., Doi, Y., Kinoshita, H., Morisaki, T., Fukuoka, T., Hasegawa, T., Kimura, K., Amano, R., and Hirakawa, K. (2016). Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1\/IGF1R Signaling under Hypoxia. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159912"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13046-024-03201-w","article-title":"CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment","volume":"43","author":"Tao","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"114972","DOI":"10.1016\/j.celrep.2024.114972","article-title":"Cancer-associated fibroblasts maintain critical pancreatic cancer cell lipid homeostasis in the tumor microenvironment","volume":"43","author":"Han","year":"2024","journal-title":"Cell Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41389-022-00434-2","article-title":"Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer","volume":"11","author":"Mello","year":"2022","journal-title":"Oncogenesis"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1158\/0008-5472.CAN-22-2316","article-title":"Hypoxia Potentiates the Inflammatory Fibroblast Phenotype Promoted by Pancreatic Cancer Cell-Derived Cytokines","volume":"83","author":"Cimino","year":"2023","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ino, Y., Yamazaki-Itoh, R., Oguro, S., Shimada, K., Kosuge, T., Zavada, J., Kanai, Y., and Hiraoka, N. (2013). Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055146"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1053\/j.gastro.2022.02.024","article-title":"Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment","volume":"162","author":"Huang","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s12967-024-05674-x","article-title":"BNIP3+ fibroblasts associated with hypoxia and inflammation predict prognosis and immunotherapy response in pancreatic ductal adenocarcinoma","volume":"22","author":"Gao","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Bigos, K.J., Quiles, C.G., Lunj, S., Smith, D.J., Krause, M., Troost, E.G., West, C.M., Hoskin, P., and Choudhury, A. (2024). Tumour response to hypoxia: Understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1331355"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Abd, G.M., Laird, M.C., Ku, J.C., and Li, Y. (2023). Hypoxia-induced cancer cell reprogramming: A review on how cancer stem cells arise. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1227884"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.tcb.2018.06.008","article-title":"The Different Routes to Metastasis via Hypoxia-Regulated Programs","volume":"28","author":"Nobre","year":"2018","journal-title":"Trends Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1073\/pnas.0611662104","article-title":"Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy","volume":"104","author":"Cairns","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semcancer.2023.11.006","article-title":"Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities","volume":"98","author":"Beckers","year":"2024","journal-title":"Semin. Cancer Biol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Fu, Z., Mowday, A.M., Smaill, J.B., Hermans, I.F., and Patterson, A.V. (2021). Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. Cells, 10.","DOI":"10.3390\/cells10051006"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1007\/s11033-019-05058-1","article-title":"Markers of pancreatic cancer stem cells and their clinical and therapeutic implications","volume":"46","author":"Gzil","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41556-019-0407-1","article-title":"CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth","volume":"21","author":"Wang","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1158\/1078-0432.CCR-14-1399","article-title":"Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms","volume":"21","author":"Cioffi","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1158\/0008-5472.CAN-11-3666","article-title":"CD24 is an effector of HIF-1-driven primary tumor growth and metastasis","volume":"72","author":"Thomas","year":"2012","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Panagiotou, E., Syrigos, N.K., Charpidou, A., Kotteas, E., and Vathiotis, I.A. (2022). CD24: A Novel Target for Cancer Immunotherapy. J. Pers. Med., 12.","DOI":"10.3390\/jpm12081235"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4174\/astr.2025.108.2.98","article-title":"Exploring the prognostic role of cluster of differentiation 47 in patients with advanced pancreatic cancer: A comparative cohort study","volume":"108","author":"Amare","year":"2025","journal-title":"Ann. Surg. Treat. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"20","DOI":"10.37349\/etat.2024.00202","article-title":"Role of STAT3 in pancreatic cancer","volume":"5","author":"Hamel","year":"2024","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/acscentsci.3c01440","article-title":"Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment","volume":"10","author":"Chen","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e202201460","DOI":"10.26508\/lsa.202201460","article-title":"STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer","volume":"5","author":"Lefler","year":"2022","journal-title":"Life Sci. Alliance"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Zhang, C., Li, N., Xue, F., and Zhang, T. (2025). SOX9 Promotes Breast Cancer Progression via the EGFR\/STAT3 Signaling Axis. Curr. Cancer Drug Targets, Epub ahead of printing.","DOI":"10.2174\/0115680096369386250717220332"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Carrasco-Garcia, E., Lopez, L., Moncho-Amor, V., Carazo, F., Aldaz, P., Collado, M., Bell, D., Gaafar, A., Karamitopoulou, E., and Tzankov, A. (2022). SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. Cancers, 14.","DOI":"10.3390\/cancers14040916"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bone.2010.10.006","article-title":"Hypoxia-inducible factor-1 is a positive regulator of Sox9 activity in femoral head osteonecrosis","volume":"48","author":"Zhang","year":"2011","journal-title":"Bone"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","article-title":"Type I collagen deletion in \u03b1SMA","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"20380","DOI":"10.18632\/oncotarget.14608","article-title":"Multiple biological functions of Twist1 in various cancers","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"111713","DOI":"10.1016\/j.yexcr.2019.111713","article-title":"TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer","volume":"386","author":"Wang","year":"2020","journal-title":"Exp. Cell Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e70586","DOI":"10.1111\/jcmm.70586","article-title":"Twist1 Regulates the Immune Checkpoint VISTA and Promotes the Proliferation, Migration and Progression of Pancreatic Cancer Cells","volume":"29","author":"Topcu","year":"2025","journal-title":"J. Cell Mol. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"25130","DOI":"10.1074\/jbc.M001914200","article-title":"Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2 sensing","volume":"275","author":"Chandel","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cmet.2005.05.001","article-title":"Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing","volume":"1","author":"Guzy","year":"2005","journal-title":"Cell Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.3748\/wjg.v27.i28.4582","article-title":"Modulation of cell physiology under hypoxia in pancreatic cancer","volume":"27","author":"Estaras","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s12276-024-01180-8","article-title":"Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer","volume":"56","author":"Bae","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/157488810790442813","article-title":"Signaling mechanism(s) of reactive oxygen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor progression","volume":"5","author":"Wang","year":"2010","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5801209","DOI":"10.1155\/2018\/5801209","article-title":"Reactive Oxygen Species-Mediated Tumor Microenvironment Transformation: The Mechanism of Radioresistant Gastric Cancer","volume":"2018","author":"Gu","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","article-title":"Targeting hypoxic tumor microenvironment in pancreatic cancer","volume":"14","author":"Tao","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41392-026-02583-x","article-title":"Reactive oxygen species (ROS) in cancer: From mechanism to therapeutic implications","volume":"11","author":"Akter","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1535-7163.MCT-11-0107","article-title":"Impact of APE1\/Ref-1 redox inhibition on pancreatic tumor growth","volume":"10","author":"Fishel","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Rapozzi, V., Comuzzi, C., Di Giorgio, E., and Xodo, L.E. (2025). Correction: KRAS and NRF2 drive metabolic reprogramming in pancreatic cancer cells: The influence of oxidative and nitrosative stress. Front. Cell Dev. Biol., 13, Erratum in Front Cell Dev Biol.\u00a02025, 13, 1547582. https:\/\/doi.org\/10.3389\/fcell.2025.1547582.","DOI":"10.3389\/fcell.2025.1661525"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"119606","DOI":"10.1016\/j.bbamcr.2023.119606","article-title":"NRF2 interacts with distal enhancer and inhibits nitric oxide synthase 2 expression in KRAS-driven pancreatic cancer cells","volume":"1871","author":"Cortolezzis","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_101","first-page":"1264","article-title":"Glutathione peroxidase 4 maintains a stemness phenotype, oxidative homeostasis and regulates biological processes in Panc-1 cancer stem-like cells","volume":"41","author":"Peng","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trsl.2018.12.008","article-title":"Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition","volume":"207","author":"Abdalla","year":"2019","journal-title":"Transl. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/boc.202000020","article-title":"Pancreatic stellate cells exhibit adaptation to oxidative stress evoked by hypoxia","volume":"112","author":"Estaras","year":"2020","journal-title":"Biol. Cell"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2014.02.003","article-title":"alpha-Mangostin inhibits hypoxia-driven ROS-induced PSC activation and pancreatic cancer cell invasion","volume":"347","author":"Lei","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/pcmr.12946","article-title":"NRF2-dependent stress defense in tumor antioxidant control and immune evasion","volume":"34","author":"Meierjohann","year":"2021","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-026-01780-z","article-title":"The distinct roles of ROS in tumor immunity: From mechanisms to immunotherapeutic applications","volume":"19","author":"Li","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3892\/ijo.2013.2229","article-title":"Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine","volume":"44","author":"Duong","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5381692","DOI":"10.1155\/2019\/5381692","article-title":"Understanding of ROS-Inducing Strategy in Anticancer Therapy","volume":"2019","author":"Kim","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cmet.2005.05.002","article-title":"Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation","volume":"1","author":"Brunelle","year":"2005","journal-title":"Cell Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1002\/1878-0261.70151","article-title":"A guide to reactive oxygen species in tumour hypoxia: Measurement and therapeutic implications","volume":"19","author":"Hacker","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMra0910283","article-title":"Hypoxia and inflammation","volume":"364","author":"Eltzschig","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1158\/0008-5472.CAN-11-1433","article-title":"Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer","volume":"73","author":"Hostetter","year":"2013","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2\u03b1 Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1158\/1535-7163.MCT-08-0510","article-title":"A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth","volume":"7","author":"Greenberger","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"29936","DOI":"10.1074\/jbc.M204733200","article-title":"Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway","volume":"277","author":"Isaacs","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-05-1235","article-title":"Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity","volume":"65","author":"Kong","year":"2005","journal-title":"Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/ja209924v","article-title":"Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL\/HIF-1\u03b1 interaction","volume":"134","author":"Buckley","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e156774","DOI":"10.1172\/JCI156774","article-title":"HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy","volume":"132","author":"Salman","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: Current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"McDonald, P.C., Chafe, S.C., and Dedhar, S. (2016). Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. Front. Cell Dev. Biol., 4.","DOI":"10.3389\/fcell.2016.00027"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.imlet.2018.05.001","article-title":"Targeting the CD73-adenosine axis in immuno-oncology","volume":"205","author":"Allard","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1084\/jem.20100587","article-title":"HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment","volume":"207","author":"Corzo","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2016.79","article-title":"Hypoxia-activated prodrugs: Paths forward in the era of personalised medicine","volume":"114","author":"Hunter","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3109\/07357907.2015.1019677","article-title":"A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma","volume":"33","author":"Borad","year":"2015","journal-title":"Cancer Investig."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/1078-0432.CCR-11-1980","article-title":"Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer","volume":"18","author":"Sun","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/ars.2022.0118","article-title":"Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination DNA Repair","volume":"39","author":"Otowa","year":"2023","journal-title":"Antioxid. Redox Signal."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41588-018-0318-2","article-title":"Molecular landmarks of tumor hypoxia across cancer types","volume":"51","author":"Bhandari","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Foehrenbacher, A., Patel, K., Abbattista, M.R., Guise, C.P., Secomb, T.W., Wilson, W.R., and Hicks, K.O. (2013). The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104. Front. Oncol., 3.","DOI":"10.3389\/fonc.2013.00263"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Krzykawska-Serda, M., Szczygie\u0142, D., Gawe\u0142, S., Drza\u0142, A., Szczygie\u0142, M., Kmie\u0107, M.M., Mackiewicz, A., Kieda, C., and Elas, M. (2023). Oxygen therapeutic window induced by myo-inositol trispyrophosphate (ITPP)-Local pO2 study in murine tumors. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0285318"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/ijc.28597","article-title":"Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy","volume":"134","author":"Raykov","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-15-3112","article-title":"Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate","volume":"22","author":"Limani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00109-013-0992-6","article-title":"Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment","volume":"91","author":"Kieda","year":"2013","journal-title":"J. Mol. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/SLA.0000000000002431","article-title":"The Allosteric Hemoglobin Effector ITPP Inhibits Metastatic Colon Cancer in Mice","volume":"266","author":"Limani","year":"2017","journal-title":"Ann. Surg."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/cbic.201000619","article-title":"Myo-InositolTrisPyroPhosphate treatment leads to HIF-1\u03b1 suppression and eradication of early hepatoma tumors in rats","volume":"12","author":"Aprahamian","year":"2011","journal-title":"Chembiochem"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e010153","DOI":"10.1136\/jitc-2024-010153","article-title":"Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients","volume":"13","author":"Nagy","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1111\/jcmm.16399","article-title":"Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response","volume":"25","author":"Brodaczewska","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"21782","DOI":"10.1038\/s41598-025-05930-0","article-title":"Potentiation of immune checkpoint blockade with an ITPP radiosensitizer studied with oxygen saturation measurements from photoacoustic imaging","volume":"15","author":"Tran","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/s41467-021-24069-w","article-title":"Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors","volume":"12","author":"Schneider","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_148","first-page":"CD005007","article-title":"Hyperbaric oxygenation for tumour sensitisation to radiotherapy","volume":"4","author":"Bennett","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11523-012-0233-x","article-title":"Hyperbaric oxygen therapy and cancer\u2014A review","volume":"7","author":"Moen","year":"2012","journal-title":"Target. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e1802228","DOI":"10.1002\/adma.201802228","article-title":"Nanoparticle-Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1002\/adma.201504617","article-title":"Perfluorocarbon-Loaded Hollow Bi2Se3 Nanoparticles for Timely Supply of Oxygen under Near-Infrared Light to Enhance the Radiotherapy of Cancer","volume":"28","author":"Song","year":"2016","journal-title":"Adv. Mater."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Abou Khouzam, R., Brodaczewska, K., Filipiak, A., Zeinelabdin, N.A., Buart, S., Szczylik, C., Kieda, C., and Chouaib, S. (2020). Tumor Hypoxia Regulates Immune Escape\/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.613114"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","article-title":"A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells","volume":"74","author":"Barsoum","year":"2014","journal-title":"Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"277ra230","DOI":"10.1126\/scitranslmed.aaa1260","article-title":"Immunological mechanisms of the antitumor effects of supplemental oxygenation","volume":"7","author":"Hatfield","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/10409238.2018.1556578","article-title":"Molecular intricacies of aerobic glycolysis in cancer: Current insights into the classic metabolic phenotype","volume":"53","year":"2018","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"39833","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/bjc.2015.284","article-title":"Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole","volume":"113","author":"Dhani","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Siddiqui, I., Bilkey, J., McKee, T.D., Serra, S., Pintilie, M., Do, T., Xu, J., Tsao, M.S., Gallinger, S., and Hill, R.P. (2022). Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomas. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.926497"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2016.34.15_suppl.4007","article-title":"MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)","volume":"34","author":"Lenz","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2967\/jnumed.115.167650","article-title":"Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on 18F-Fluoroazomyin Arabinoside Uptake","volume":"57","author":"Yeung","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.radonc.2015.05.009","article-title":"Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer","volume":"116","author":"Klaassen","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/1878-0261.12688","article-title":"Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: Preliminary experience","volume":"14","author":"Klaassen","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Liu, D., Steins, A., Klaassen, R., van der Zalm, A.P., Bennink, R.J., van Tienhoven, G., Besselink, M.G., Bijlsma, M.F., and van Laarhoven, H.W.M. (2020). Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. Biomedicines, 8.","DOI":"10.3390\/biomedicines8110444"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mri.2018.02.005","article-title":"Repeatability and correlations of dynamic contrast enhanced and T2* MRI in patients with advanced pancreatic ductal adenocarcinoma","volume":"50","author":"Klaassen","year":"2018","journal-title":"Magn. Reson. Imaging"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ijrobp.2018.04.064","article-title":"Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients","volume":"102","author":"Klaassen","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.21037\/tcr-22-787","article-title":"High expression of hypoxia-inducible factor 1-alpha predicts poor prognosis in pancreatic ductal adenocarcinoma: A meta-analysis and database validation protocol","volume":"11","author":"Zoa","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s12253-017-0284-5","article-title":"Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma","volume":"24","author":"Yang","year":"2018","journal-title":"Pathol. Oncol. Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.21037\/jgo-24-560","article-title":"LDHA as a predictive biomarker and its association with the infiltration of immune cells in pancreatic adenocarcinoma","volume":"15","author":"Zheng","year":"2024","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.3748\/wjg.v30.i44.4689","article-title":"Hypoxia-related bioinformatic signatures associated with prognosis and tumor microenvironment of pancreatic cancer: Current status, concerns, and future perspectives","volume":"30","author":"Li","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.3748\/wjg.v30.i36.4057","article-title":"Construction and validation of a pancreatic cancer prognostic model based on genes related to the hypoxic tumor microenvironment","volume":"30","author":"Yang","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"15330338241288687","DOI":"10.1177\/15330338241288687","article-title":"Establishment of a Prognostic Model for Pancreatic Cancer Based on Hypoxia-Related Genes","volume":"23","author":"Wu","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/sj.bjc.6605450","article-title":"Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene","volume":"102","author":"Buffa","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Sadozai, H., Acharjee, A., Kayani, H.Z., Gruber, T., Gorczynski, R.M., and Burke, B. (2024). High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1360629"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.semcancer.2023.11.008","article-title":"Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy","volume":"97","author":"Janji","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"20180036","DOI":"10.1259\/bjr.20180036","article-title":"Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy","volume":"92","author":"Yang","year":"2019","journal-title":"Br. J. Radiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/3873\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:25:40Z","timestamp":1781684740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/3873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":176,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27093873"],"URL":"https:\/\/doi.org\/10.3390\/ijms27093873","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]}}}